Latest news
Watch: TVG CEO Jeremy Salt on Syva collaboration and what’s next for the company
The Vaccine Group has entered a collaboration with global animal health group Syva to develop a vaccine against zoonotic pig disease Streptococcus suis. CEO Jeremy Salt discusses the partnership, other vaccine developments and the company’s work on biotherapeutics.
Read moreAnimal health group Syva to collaborate with The Vaccine Group
The Vaccine Group has entered into a collaboration with leading Spanish animal health group Syva to develop a vaccine against Streptococcus suis, an economically damaging and zoonotic pig disease.
Read moreWatch: DeakinBio CEO Aled Roberts’ TEDx talk on lessons from Martian materials engineering
From stone, to copper, then bronze, iron, steel, concrete, plastics and now silicon, human technological progress has always been underpinned by advancements in materials science. In this talk, Aled explains how investigating the enormous challenges associated with colonising the Moon and Mars led him on an accidental journey to discover how innovations in material science could have a huge impact here on Earth.
Read moreOur portfolio
Our portfolio companies are involved in developing a wide range of technologies based on cutting-edge intellectual property to meet the needs and demands of the world.
See all companiesDeakinBio
DeakinBio has developed a technology, termed BioSintering®, to produce advanced bio-based materials from organic waste such as chickpea broth or algae, along with widely available inorganic powders such as crushed limestone.
Learn moreShare price
Share Price InformationLatest downloads
Half Year Results 2024/25
